Platinum Investment Management’s Structure Therapeutics GPCR Stock Holding History

Platinum Investment Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.22M	Sell	66,864 -21,010	-24%	-$1.44M	0.81%	46
2025 Q4	$6.11M	Sell	87,874 -34,884	-28%	-$1.42M	1.41%	15
2025 Q3	$3.44M	Buy	122,758 +47,858	+64%	+$953K	0.22%	48
2025 Q2	$1.55M	Hold	74,900	–	–	0.1%	64
2025 Q1	$1.3M	Hold	74,900	–	–	0.08%	65
2024 Q4	$2.03M	Buy	74,900 +17,670	+31%	+$627K	0.12%	61
2024 Q3	$2.51M	Hold	57,230	–	–	0.11%	62
2024 Q2	$2.25M	Sell	57,230 -19,863	-26%	-$816K	0.09%	63
2024 Q1	$3.3M	Hold	77,093	–	–	0.13%	54
2023 Q4	$3.14M	Buy	77,093 +24,632	+47%	+$1.41M	0.13%	66
2023 Q3	$2.65M	Buy	52,461 +37,461	+250%	+$1.21M	0.1%	69
2023 Q2	$624K	Hold	15,000	–	–	0.02%	102
2023 Q1	$357K	Buy	+15,000	New	+$352K	0.01%	111

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Platinum Investment Management's GPCR Position: Q1 2026 in Review

Platinum Investment Management reduced its Structure Therapeutics (GPCR) stake by 24% in Q1 2026, selling an estimated $1.44M and leaving 66,864 shares worth $3.22M. The position accounts for 0.81% of the portfolio, ranked #46.

Platinum Investment Management first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $6.11M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Platinum Investment Management held 66,864 shares of Structure Therapeutics worth $3.22M as of Q1 2026.
Platinum Investment Management sold 21,010 Structure Therapeutics shares in Q1 2026, an estimated $1.44M.
Structure Therapeutics made up 0.81% of Platinum Investment Management's portfolio in Q1 2026, its #46 holding.
Platinum Investment Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
Platinum Investment Management's Structure Therapeutics position peaked at $6.11M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Platinum Investment Management's 13F filing for Q1 2026, filed 14 May 2026.